Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy (original) (raw)
Antitumor activity of MEK and PI3K inhibitors in malignant pleural mesothelioma
Tatsuhiko Miyazaki
European Respiratory Journal, 2011
View PDFchevron_right
Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features
Didier Jean
Cancer Research, 2020
View PDFchevron_right
Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
Wen-Bin Ou
British Journal of Cancer, 2014
View PDFchevron_right
Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma
Atsuo Takashima
Japanese Journal of Clinical Oncology, 2019
View PDFchevron_right
Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo
Tatsuhiko Miyazaki
International journal of oncology, 2012
View PDFchevron_right
Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma
Marcello Guaglio
International Journal of Molecular Sciences
View PDFchevron_right
Malignant peritoneal mesothelioma: a review
Glenn Broeckx
Translational Lung Cancer Research
View PDFchevron_right
Systemic chemotherapy in the management of malignant peritoneal mesothelioma
Luis Paz-ares
European Journal of Surgical Oncology (EJSO), 2006
View PDFchevron_right
Open-Label Study of Pemetrexed Alone or in Combination with Cisplatin for the Treatment of Patients with Peritoneal Mesothelioma: Outcomes of an Expanded Access Program
Chandra Belani
Clinical Lung Cancer, 2005
View PDFchevron_right
Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study
tatsunori shimoi
BMC Cancer
View PDFchevron_right
Long-Term Survival of More than 5 Years with Maintenance Therapy Using Single-Agent Pemetrexed in a Patient with Diffuse Malignant Peritoneal Mesothelioma
Naoshi Nishida
Case Reports in Medicine, 2023
View PDFchevron_right
Systemic chemotherapy with pemetrexed and cisplatin for malignant peritoneal mesothelioma: A single institution experience
George Lainakis
Tumori, 2011
View PDFchevron_right
Malignant Peritoneal Mesothelioma: Treatment Options and Survival
Tuomo Rantanen
Anticancer Research, 2019
View PDFchevron_right
Efficacy of a second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study
tatsunori shimoi
Research Square (Research Square), 2021
View PDFchevron_right
Challenges in the diagnosis and treatment of peritoneal mesothelioma: a case study and review of the literature
Joanna Szpor
Oncology in Clinical Practice
View PDFchevron_right
Therapies currently in Phase II trials for malignant pleural mesothelioma
Daniela D Tavian
Expert Opinion on Investigational Drugs, 2013
View PDFchevron_right
Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference
Robert Taub
Annals of Oncology, 2006
View PDFchevron_right
A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma
Federica D'Antonio
Lung Cancer, 2020
View PDFchevron_right
MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma
Immanuel Dhanasingh
PLoS ONE, 2014
View PDFchevron_right
Integrative genomic analysis of peritoneal malignant mesothelioma: Understanding a case with extraordinary chemotherapy response
Bastian Fromm
Molecular Case Studies
View PDFchevron_right
Diagnostic and Therapeutic Pathway in Diffuse Malignant Peritoneal Mesothelioma
Enrico Pasqual
Cancers, 2023
View PDFchevron_right
56: Multiple RTK targeting as a therapeutic option in malignant pleural mesothelioma
Kieran Crosbie Staunton
Lung Cancer, 2017
View PDFchevron_right
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma
Immanuel Dhanasingh
Scientific Reports, 2016
View PDFchevron_right
Advances in malignant peritoneal mesothelioma
Dian Ding
International journal of colorectal disease, 2015
View PDFchevron_right
Emerging Drug Therapies for Mesothelioma
Vijayalakshmi Shridhar
Mesothelioma, 2020
View PDFchevron_right
Chemotherapy for malignant pleural mesothelioma: past results and recent developments
Sandra Tomek
Lung Cancer, 2004
View PDFchevron_right
Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets
Tullio Florio
Biochemical Pharmacology, 2011
View PDFchevron_right
Prolonged response to pemetrexed-based chemotherapy in a patient with peritoneal mesothelioma: a case report and review of the literature
Hana Študentová
Pteridines, 2016
View PDFchevron_right
Phase II Study of Erlotinib in Patients With Malignant Pleural Mesothelioma: A Southwest Oncology Group Study
Joseph Testa
Journal of Clinical Oncology, 2007
View PDFchevron_right
Suppression of pro-metastasis phenotypes expression in malignant pleural mesothelioma by the PI3K inhibitor LY294002 or the MEK inhibitor UO126
Annette Alleva
Anticancer …, 2006
View PDFchevron_right
Nivolumab for Pediatric Malignant Peritoneal Mesothelioma
Handan Dinçaslan
View PDFchevron_right
State of the Art: Concise Review Scientific Advances and New Frontiers in Mesothelioma Therapeutics
Michele Carbone
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2018
View PDFchevron_right
Chemotherapy for malignant pleural mesothelioma
Jason Lester
Current Opinion in Oncology, 2003
View PDFchevron_right
Incidence, Survival Analysis and Future Perspective of Primary Peritoneal Mesothelioma (PPM): A Population-Based Study from SEER Database
Asad Ullah
Cancers
View PDFchevron_right